

Vancomycin-Resistant Enterococcus Faecium Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/V70B20C3CF3DEN.html>

Date: September 2022

Pages: 78

Price: US\$ 2,000.00 (Single User License)

ID: V70B20C3CF3DEN

Abstracts

Vancomycin-Resistant Enterococcus Faecium Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2022, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2022,

provides comprehensive information on the therapeutics under development for Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant *Enterococcus faecium* Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 2, 14 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Vancomycin-Resistant *Enterococcus faecium* Infections - Overview

Vancomycin-Resistant *Enterococcus faecium* Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Vancomycin-Resistant *Enterococcus faecium* Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vancomycin-Resistant *Enterococcus faecium* Infections - Companies Involved in
Therapeutics Development

Vancomycin-Resistant *Enterococcus faecium* Infections - Drug Profiles

Vancomycin-Resistant *Enterococcus faecium* Infections - Dormant Projects

Vancomycin-Resistant *Enterococcus faecium* Infections - Discontinued Products

Vancomycin-Resistant *Enterococcus faecium* Infections - Product Development
Milestones

Featured News & Press Releases

Nov 26, 2018: MicuRx enrolls first patient in a phase 2 clinical trial in U.S. for novel
antibiotic, Contezolid Acefosamil

Nov 29, 2016: MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent
MRX-4

Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I

Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second
Phase of Lantibiotics Project

Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress
Towards Commercial Production of Lead Lantibiotic MU1140

May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation
Antibacterial Agent

Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I

Appendix

Methodology

Coverage

Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Acurx Pharmaceuticals Inc, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Arietis Corp, 2022
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Curza Global LLC, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Daiichi Sankyo Co Ltd, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Gnubiotics Sciences SA, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Karveel Pharmaceuticals, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MetalloBio Ltd, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Ltd, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals Inc, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Naicons Srl, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Opal Biosciences Ltd, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by QureTech Bio AB, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Rebiotix Inc, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sano Chemicals Inc, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals Inc, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Seres Therapeutics Inc, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, 2022

Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, 2022 (Contd..1)

Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Vancomycin-Resistant Enterococcus Faecium Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/V70B20C3CF3DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V70B20C3CF3DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

